Hyper ® Wins Dual CES 2026 Innovation Awards ® for its Breakthrough Tech Accessories
5.11.2025 22:50:00 CET | Business Wire | Press Release
Hyper®, a leader in mobile tech accessories for creators and power users, today announced it has been honored with two CES2026 Innovation Awards® in the Consumer Peripherals and Accessories category. These awards reflect Hyper’s mission to build breakthrough solutions that help users create, connect, and go beyond the limits of their devices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105297377/en/
CES Innovation Awards® 2026 Honorees: HyperSpace™ Trackpad Pro and HyperDrive® Next redefine haptics, personalization, and next-gen USB4 V2 speed.
The CES Innovation Awards program is an annual competition that honors the most innovative, new products in consumer technology, recognizing top innovations across multiple categories.
“For 20 years, Hyper has led the tech accessory space with industry-defining ‘world’s firsts’ in power, connectivity, mobility, and desktop solutions,” said Gabi Iorio, Director of Global Marketing and Sales, Hyper. “Our CES Innovation Awards 2026 Honorees are a powerful validation of our company’s continual and relentless commitment to challenge convention, push boundaries, and deliver transformative technology to today’s mobile tech users.”
Hyper’s CES Innovation Awards® 2026 Honorees
HyperSpace™ Trackpad Pro (HS2510GL)
The first premium haptic trackpad purpose-built for Microsoft® Windows®, the HyperSpace™ Trackpad Pro delivers zero-latency input, 240Hz responsiveness, and independent pressure sensing for up to 10 fingers. Powered by Hydra® Connect software, users can create app-specific shortcuts, gesture zones, and deep-click profiles for unmatched precision and personalization. Its ergonomic design, smart palm rejection, and community-driven shortcut sharing make it a game-changer for digital creators and multitaskers.
The HyperSpace Trackpad Pro (HS2510GL) is now available for pre-order on Kickstarter, with early bird pricing starting at $90 and arriving in Q1 2026.
HyperDrive® Next USB4 M.2 PCIe Enclosure (HD2500GL)
This modular, high-speed expansion solution delivers 64Gbps PCIe throughput, supports AI accelerators and networking cards, and features a hybrid power system for stable performance—even on low-power devices. Built on Intel’s Barlow Ridge chipset, it offers tool-less installation, IP55-rated durability, and is constructed from 100% recycled aluminum, making it a sustainable, future-ready accessory for professionals.
The HyperDrive® Next USB4 M.2 PCIe Enclosure (HD2500GL) will be available starting at the end of Q4 2025, with a retail price of $199.99.
See Hyper’s Innovations at CES 2026
Consumers, media, and industry professionals can experience both award-winning products firsthand at CES 2026, the world’s most influential tech event happening in Las Vegas from January 6–9, 2026. Hyper will showcase its latest innovations alongside Targus, Hyper’s parent company, in their Suite #35-106 at The Venetian. Additionally, both of these CES Innovation Awards Honorees will be featured in the CES Innovation Awards Showcase and during CES Unveiled, the premier media preview event taking place at the Mandalay Bay Convention Center on the evening of January 4.
About HYPER®
Celebrating 20 years of enabling creators and innovators to Go Beyond, Hyper® specializes in delivering cutting-edge tech and mobile accessories to creative professionals with its award-winning lineup of power, connectivity, mobility, and desktop solutions. Learn more at hypershop.com and follow us on Instagram, TikTok, X, and LinkedIn.
About CES®
CES is the most powerful tech event in the world – the proving ground for breakthrough technologies and global innovators. This is where the world's biggest brands do business and meet new partners, and the sharpest innovators hit the stage. Owned and produced by the Consumer Technology Association (CTA)®, CES features every aspect of the tech sector. CES 2026 takes place Jan. 6-9, 2026, in Las Vegas. Learn more at CES.tech and follow CES on social.
About Consumer Technology Association (CTA)®
As North America’s largest technology trade association, CTA is the tech sector. Our members are the world’s leading innovators – from startups to global brands – helping support more than 18 million American jobs. CTA owns and produces CES® – the most powerful tech event in the world. Find us at CES.tech. Follow us @CTAtech. The CES Innovation Awards 2026 Honorees, including product descriptions and photos, can be found at CES.tech/innovation. More will be revealed in January. Many honorees will display their winning products in the Innovation Awards Showcase at CES 2026.
Prices, dates, features, and specifications are subject to change without notice. ©2025 Hyper. Hyper, HyperDrive, and HyperSpace are trademarks or registered trademarks of Targus International LLC in the US and certain other countries. Hydra is a registered trademark of Peratech Holdco Limited. Adobe Premiere Pro, Illustrator and Photoshop are either registered trademarks or trademarks of Adobe in the United States and/or other countries. Microsoft, Windows, and Microsoft Office are registered trademarks of the Microsoft group of companies. Figma is a registered trademark of Figma, Inc. macOS is a trademark of Apple Inc., registered in the U.S. and other countries and regions. All other trademarks and registered trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251105297377/en/
Contacts
For more information, contact:
Rachel Neppes - rneppes@targus.com – Head of PR
714-575-7432
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom